HF
KRYS icon

HRT Financial’s Krystal Biotech KRYS Stock Holding History

HRT Financial’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-4,680
Closed -$843K – 3139
2025
Q1 		$843K Sell
4,680
-17,327
-79% -$2.91M 0.01% 1194
2024
Q4 		$3.45M Buy
+22,007
New +$3.9M 0.02% 532
2024
Q2 		– Sell
-8,536
Closed -$1.52M – 2680
2024
Q1 		$1.52M Sell
8,536
-14,350
-63% -$1.99M 0.01% 687
2023
Q4 		$2.84M Buy
+22,886
New +$2.54M 0.02% 509
2023
Q1 		– Sell
-5,694
Closed -$451K – 2855
2022
Q4 		$451K Buy
+5,694
New +$423K 0.01% 1494
2022
Q1 		– Sell
-12,110
Closed -$847K – 3487
2021
Q4 		$847K Buy
+12,110
New +$705K ﹤0.01% 1274

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

HRT Financial's KRYS Position: Q2 2025 in Review

HRT Financial sold out of Krystal Biotech (KRYS) in Q2 2025, closing a stake of 4,680 shares — an estimated $843K sold.

HRT Financial first reported a position in KRYS in Q4 2021 and held it in 6 quarters. The position peaked at $3.45M in Q4 2024. 275 funds tracked by Wall St. Rank hold KRYS as of Q2 2025.

  • HRT Financial reported no remaining Krystal Biotech position as of Q2 2025 after selling out during the quarter.
  • HRT Financial sold 4,680 Krystal Biotech shares in Q2 2025, an estimated $843K.
  • HRT Financial first reported a position in Krystal Biotech in Q4 2021 and held it in 6 quarters.
  • HRT Financial's Krystal Biotech position peaked at $3.45M in Q4 2024.
  • 275 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2025.

Based on HRT Financial's 13F filing for Q2 2025, filed 14 Aug 2025.